3P Biopharmaceuticals and Norwegian biopharmaceutical company, Nordic Nanovector, have extended their collaboration agreement for the development of Betalutin. The two companies started their collaboration in 2013 and successfully advanced Betalutin. The current agreement is consolidating the relationship describing how both companies will progress the project up to regulatory submission, including development, clinical supply and late stage activities, such as process characterization and validation. 

“Our partnership with Nordic Nanovector is a great example of how together we can achieve more than planned and succeed in the late stage of Betalutin development,” said Dámaso Molero, general manager at 3P Biopharmaceuticals. He also added “this project demonstrates how we can bring together various parties to successfully reach the project goals by using complex technologies in this challenging project.”